Sidley Represents Underwriters in Connection With Pharvaris’ US$115 Million Underwritten Offering of Ordinary Shares

Sidley is representing Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities as joint book-running managers, in connection with Pharvaris N.V.’s (“Pharvaris”) underwritten offering of 3,874,664 of its ordinary shares at a price of US$29.68 per share. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 11, 2026, subject to satisfaction of customary closing conditions.

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema.

The deal team is being led by Frank Rahmani, Sam Gandhi, and Natalie Karam, and includes Derek Rogers and Charles Santoro (Capital Markets), Emily Marden and Jaclyn Fonteyne (Food, Drug and Medical Devices), Alison Lehner and Lauren Grau (Technology and Life Sciences Transactions), and Jonathan Westreich and Sophie Arkusinski (Tax).